Total Payments
$117,092
2024 Payments
$713.61
Companies
38
Transactions
699
Medicare Patients
37,722
Medicare Billing
$8.0M
Payment Breakdown by Category
Other$97,797 (83.5%)
Food & Beverage$15,152 (12.9%)
Travel$2,870 (2.5%)
Consulting$1,188 (1.0%)
Education$85.70 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,797 | 46 | 83.5% |
| Food and Beverage | $15,152 | 627 | 12.9% |
| Travel and Lodging | $2,870 | 15 | 2.5% |
| Consulting Fee | $1,188 | 3 | 1.0% |
| Education | $85.70 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $49,140 | 97 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29,845 | 51 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $19,736 | 30 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $7,160 | 13 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,929 | 132 | $0 (2024) |
| ABIOMED | $1,509 | 24 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,138 | 25 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,015 | 74 | $0 (2024) |
| PFIZER INC. | $977.23 | 69 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $824.47 | 59 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $713.61 | 40 | Novartis Pharmaceuticals Corporation ($196.19) |
| 2023 | $1,176 | 56 | Novartis Pharmaceuticals Corporation ($260.28) |
| 2022 | $1,068 | 53 | Novartis Pharmaceuticals Corporation ($181.07) |
| 2021 | $758.72 | 44 | Novartis Pharmaceuticals Corporation ($153.99) |
| 2020 | $8,791 | 67 | Amgen Inc. ($7,028) |
| 2019 | $17,193 | 106 | Amgen Inc. ($9,168) |
| 2018 | $34,320 | 168 | Amgen Inc. ($12,636) |
| 2017 | $53,071 | 165 | Boehringer Ingelheim Pharmaceuticals, Inc. ($22,532) |
All Payment Transactions
699 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/05/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/08/2024 | Medtronic, Inc. | SYMPLICITY G3 (Device) | Food and Beverage | In-kind items and services | $35.32 | General |
| Category: Renal Denervation System | ||||||
| 11/08/2024 | Medtronic, Inc. | SYMPLICITY G3 (Device) | Food and Beverage | In-kind items and services | $29.27 | General |
| Category: Renal Denervation System | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.07 | General |
| Category: Cardiovascular | ||||||
| 10/10/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Cardiology | ||||||
| 10/09/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Cardiology | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/18/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/07/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: Cardiology | ||||||
| 08/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: DIABETES | ||||||
| 07/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Cardiology | ||||||
| 07/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/26/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $18.99 | General |
| Category: Cardiovascular | ||||||
| 06/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/23/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: Cardiology | ||||||
| 05/15/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/09/2024 | Itamar Medical Inc | WatchPATONE (Device) | Food and Beverage | Cash or cash equivalent | $11.78 | General |
| Category: Sleep Apnea testing | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 57 | 9,176 | 21,323 | $4.8M | $1.8M |
| 2022 | 55 | 9,189 | 22,567 | $5.7M | $2.0M |
| 2021 | 55 | 9,481 | 27,495 | $6.2M | $2.2M |
| 2020 | 54 | 9,876 | 25,497 | $5.9M | $2.0M |
Total Patients
37,722
Total Services
96,882
Medicare Billing
$8.0M
Procedure Codes
227
All Medicare Procedures & Services
227 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0422 | Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session | Office | 2023 | 252 | 4,778 | $697,128 | $421,928 | 60.5% |
| G0423 | Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session | Office | 2023 | 243 | 4,460 | $651,490 | $394,880 | 60.6% |
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 272 | 272 | $1.1M | $293,632 | 27.1% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 272 | 277 | $195,270 | $147,685 | 75.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 986 | 1,567 | $281,250 | $133,189 | 47.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 710 | 723 | $685,348 | $91,028 | 13.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,141 | 1,318 | $158,160 | $77,081 | 48.7% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 328 | 334 | $172,665 | $40,964 | 23.7% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Office | 2023 | 245 | 245 | $72,025 | $31,061 | 43.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 65 | 612 | $55,080 | $26,802 | 48.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,742 | 2,299 | $131,016 | $22,375 | 17.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 124 | 496 | $62,000 | $21,372 | 34.5% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 29 | 29 | $43,500 | $16,665 | 38.3% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 36 | 332 | $36,520 | $13,987 | 38.3% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 84 | 84 | $52,760 | $13,339 | 25.3% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 95 | 95 | $49,330 | $11,583 | 23.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 105 | 105 | $24,150 | $11,124 | 46.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 58 | 58 | $19,140 | $7,114 | 37.2% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 132 | 135 | $46,170 | $5,932 | 12.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 65 | $11,050 | $5,761 | 52.1% |
| 93241 | Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 24 | 24 | $8,310 | $4,130 | 49.7% |
| 76706 | Ultrasound scan of abdominal aorta | Office | 2023 | 39 | 39 | $7,800 | $3,756 | 48.2% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 215 | 271 | $13,550 | $3,547 | 26.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 43 | 94 | $6,992 | $3,265 | 46.7% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 25 | 26 | $12,220 | $3,202 | 26.2% |
About Dr. Wade May, MD
Dr. Wade May, MD is a Cardiovascular Disease healthcare provider based in Lafayette, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1861682239.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wade May, MD has received a total of $117,092 in payments from pharmaceutical and medical device companies, with $713.61 received in 2024. These payments were reported across 699 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($97,797).
As a Medicare-enrolled provider, May has provided services to 37,722 Medicare beneficiaries, totaling 96,882 services with total Medicare billing of $8.0M. Data is available for 4 years (2020–2023), covering 227 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Lafayette, LA
- Active Since 07/31/2007
- Last Updated 08/19/2009
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1861682239
Products in Payments
- Repatha (Biological) $48,894
- PRADAXA (Drug) $29,322
- PRALUENT (Drug) $19,701
- PRALUENT ALIROCUMAB INJECTION (Biological) $6,101
- ENTRESTO (Drug) $1,592
- Impella (Device) $1,423
- ELIQUIS (Drug) $1,266
- PRALUENT (Biological) $1,059
- XARELTO (Drug) $1,015
- MK-1242 (Drug) $770.92
- JARDIANCE (Drug) $523.27
- VERQUVO (Drug) $366.77
- LEQVIO (Drug) $320.17
- Perclose ProGlide suture mediated closure system (Device) $300.14
- ENROUTE Transcarotid Neuroprotection System (Device) $276.29
- Vascepa (Drug) $270.98
- Corlanor (Drug) $245.65
- CAMZYOS (Drug) $235.21
- LifeVest (Device) $218.89
- CHANTIX (Drug) $180.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Lafayette
Dr. Ankur Lodha, M.d, M.D
Cardiovascular Disease — Payments: $547,830
Cardiovascular Disease $547,830
Agostino Ingraldi, M.d, M.D
Cardiovascular Disease — Payments: $465,987
Cardiovascular Disease $465,987
Raghotham Patlola, Md, MD
Cardiovascular Disease — Payments: $233,594
Cardiovascular Disease $233,594
Dr. Louis Salvaggio, M.d, M.D
Cardiovascular Disease — Payments: $193,985
Cardiovascular Disease $193,985
Eric Thomassee, Md, MD
Cardiovascular Disease — Payments: $147,529
Cardiovascular Disease $147,529
Dr. Eoin Donnellan
Cardiovascular Disease — Payments: $45,504
Cardiovascular Disease $45,504